(ACIU) AC Immune - Ratings and Ratios
Antibody, Vaccine, Diagnostic, Inhibitor, Aggregation
ACIU EPS (Earnings per Share)
ACIU Revenue
Description: ACIU AC Immune October 29, 2025
AC Immune SA (NASDAQ: ACIU) is a Swiss clinical-stage biopharma focused on neurodegenerative diseases caused by protein misfolding. It leverages two proprietary platforms-SupraAntigen (immunotherapy) and Morphomer (small-molecule aggregation inhibitors)-to create biologics and small molecules that selectively bind misfolded proteins such as amyloid-β, Tau, α-synuclein, TDP-43 and NLRP3.
The current pipeline includes: (1) Crenezumab, a conformation-specific anti-amyloid-β monoclonal antibody intended to slow Alzheimer’s disease (AD) progression; (2) Semorinemab, an anti-Tau antibody that targets the N-terminal region to block Tau propagation; (3) ACI-24.060 for Down-syndrome-related AD; (4) ACI-7104.056 for Parkinson’s disease; and (5) ACI-35.030, an active-immunotherapy designed to elicit endogenous antibodies against phosphorylated Tau. Diagnostic programs feature PI-2620 (Tau PET for AD and non-AD tauopathies) and ACI-12589 (α-syn PET for differential diagnosis of multiple system atrophy).
As of the most recent 10-Q (Q2 2024), AC Immune reported cash and cash equivalents of roughly €115 million, giving it an estimated 12-month runway at current burn rates (~€9-10 M per quarter). The company holds over 150 patents worldwide and has active collaborations with Genentech, Janssen, Eli Lilly and Life Molecular Imaging, which together provide up-front payments and milestone potential exceeding $200 million (per disclosed agreements).
The neuro-degenerative therapeutics market is expanding at a compound annual growth rate of ~ 9 % (2023-2030) driven by an aging global population and limited disease-modifying options. However, the sector remains high-risk; historical phase-III failure rates for AD antibodies exceed 80 %, making trial design and biomarker validation critical success factors.
For a deeper quantitative assessment of ACIU’s valuation relative to peers, you might explore the analytics on ValueRay.
ACIU Stock Overview
| Market Cap in USD | 361m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-09-23 |
ACIU Stock Ratings
| Growth Rating | -9.05% |
| Fundamental | 34.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -4.07% |
| Analyst Rating | 4.75 of 5 |
ACIU Dividends
Currently no dividends paidACIU Growth Ratios
| Growth Correlation 3m | 86.6% |
| Growth Correlation 12m | -24.9% |
| Growth Correlation 5y | -68.7% |
| CAGR 5y | 5.78% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.08 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.17 |
| Sharpe Ratio 12m | -1.32 |
| Alpha | -13.72 |
| Beta | 1.555 |
| Volatility | 91.38% |
| Current Volume | 547.8k |
| Average Volume 20d | 449.1k |
| Stop Loss | 3.1 (-8.3%) |
| Signal | -1.06 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-50.5m TTM) > 0 and > 6% of Revenue (6% = 1.74m TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -41.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 113.6% (prev 494.7%; Δ -381.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -42.6m > Net Income -50.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (100.6m) change vs 12m ago 1.09% (target <= -2.0% for YES) |
| Gross Margin 49.92% (prev -266.9%; Δ 316.9pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.52% (prev 6.81%; Δ 6.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -301.4 (EBITDA TTM -48.0m / Interest Expense TTM 167.0k) >= 6 (WARN >= 3) |
Altman Z'' -11.10
| (A) 0.17 = (Total Current Assets 131.8m - Total Current Liabilities 99.0m) / Total Assets 190.2m |
| (B) -2.14 = Retained Earnings (Balance) -407.0m / Total Assets 190.2m |
| warn (B) unusual magnitude: -2.14 — check mapping/units |
| (C) -0.24 = EBIT TTM -50.3m / Avg Total Assets 213.9m |
| (D) -3.50 = Book Value of Equity -404.7m / Total Liabilities 115.5m |
| Total Rating: -11.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.90
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -26.50% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda 0.43 = 2.36 |
| 6. ROIC - WACC (= -60.45)% = -12.50 |
| 7. RoE -49.04% = -2.50 |
| 8. Rev. Trend 21.35% = 1.60 |
| 9. EPS Trend 38.86% = 1.94 |
What is the price of ACIU shares?
Over the past week, the price has changed by +20.28%, over one month by +11.18%, over three months by +55.05% and over the past year by +13.80%.
Is AC Immune a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACIU is around 3.18 USD . This means that ACIU is currently overvalued and has a potential downside of -5.92%.
Is ACIU a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACIU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.7 | 186.4% |
| Analysts Target Price | 9.7 | 186.4% |
| ValueRay Target Price | 3.6 | 7.7% |
ACIU Fundamental Data Overview October 29, 2025
P/E Forward = 11.236
P/S = 12.4889
P/B = 3.3554
Beta = 1.555
Revenue TTM = 28.9m CHF
EBIT TTM = -50.3m CHF
EBITDA TTM = -48.0m CHF
Long Term Debt = 4.92m CHF (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.04m CHF (from shortTermDebt, last quarter)
Debt = 4.92m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = -20.8m CHF (from netDebt column, last quarter)
Enterprise Value = 164.6m CHF (286.8m + Debt 4.92m - CCE 127.1m)
Interest Coverage Ratio = -301.4 (Ebit TTM -50.3m / Interest Expense TTM 167.0k)
FCF Yield = -26.50% (FCF TTM -43.6m / Enterprise Value 164.6m)
FCF Margin = -150.8% (FCF TTM -43.6m / Revenue TTM 28.9m)
Net Margin = -174.7% (Net Income TTM -50.5m / Revenue TTM 28.9m)
Gross Margin = 49.92% ((Revenue TTM 28.9m - Cost of Revenue TTM 14.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 0.87 (Enterprise Value 164.6m / Total Assets 190.2m)
Interest Expense / Debt = 1.02% (Interest Expense 50.0k / Debt 4.92m)
Taxrate = -0.0% (0.0 / -21.2m)
NOPAT = -50.3m (EBIT -50.3m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 1.33 (Total Current Assets 131.8m / Total Current Liabilities 99.0m)
Debt / Equity = 0.07 (Debt 4.92m / totalStockholderEquity, last quarter 74.7m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -20.8m / EBITDA -48.0m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -20.8m / FCF TTM -43.6m)
Total Stockholder Equity = 103.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.55% (Net Income -50.5m / Total Assets 190.2m)
RoE = -49.04% (Net Income TTM -50.5m / Total Stockholder Equity 103.0m)
RoCE = -46.65% (EBIT -50.3m / Capital Employed (Equity 103.0m + L.T.Debt 4.92m))
RoIC = -48.88% (negative operating profit) (NOPAT -50.3m / Invested Capital 103.0m)
WACC = 11.57% (E(286.8m)/V(291.7m) * Re(11.75%) + D(4.92m)/V(291.7m) * Rd(1.02%) * (1-Tc(-0.0)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 7.71%
Fair Price DCF = unknown (Cash Flow -43.6m)
EPS Correlation: 38.86 | EPS CAGR: 157.2% | SUE: 0.83 | # QB: 0
Revenue Correlation: 21.35 | Revenue CAGR: -33.03% | SUE: -0.05 | # QB: 0
Additional Sources for ACIU Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle